Changes of metallothionein I + II proteins in the brain after 1-methyl-4-phenylpyridinium administration in mice

Patricia Rojas, Juan Hidalgo, Manuchair Ebadi, Camilo Rios

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)

Abstract

1. 1-Methyl-4-phenylpyridinium (MPP+) is a drug that induces a Parkinson's-like syndrome in several species. Oxidative stress resulting from either excess generation or reduced scavenging of free radicals has been proposed to play a role in its neurotoxicity. 2. It has been suggested that metallothionein (MT) protects against oxidative damage of the central nervous system produced by overproduction of free radicals. 3. This study examined the effect of MPP+ on metallothionein I+II protein content in different brain regions. 4. NIH mice were injected with MPP+ (4.5, 9.0 or 18 μg/ 3 μl) into their right lateral ventricle. 5. Corpus striatum, cerebellum, midbrain, frontal cortex and hippocampus were dissected out and their metallothionein concentrations were analyzed by radioimmunoassay. 6. MPP+ reduced the concentration of MT I+II proteins (38%) only in the striatum. 7. The results suggest that changes in MT I+II content may be associated with MPP+ neurotoxicity.
Original languageEnglish
Pages (from-to)143-154
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume24
DOIs
Publication statusPublished - 1 Jan 2000

Keywords

  • Free radicals
  • MPP+
  • Metallothionein
  • Oxidative stress
  • Parkinson's disease

Fingerprint Dive into the research topics of 'Changes of metallothionein I + II proteins in the brain after 1-methyl-4-phenylpyridinium administration in mice'. Together they form a unique fingerprint.

  • Cite this

    Rojas, P., Hidalgo, J., Ebadi, M., & Rios, C. (2000). Changes of metallothionein I + II proteins in the brain after 1-methyl-4-phenylpyridinium administration in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 24, 143-154. https://doi.org/10.1016/S0278-5846(99)00077-9